Full-Time

Senior Director

Clinical Science

Posted on 7/26/2024

Lyell Immunopharma

Lyell Immunopharma

201-500 employees

Develops advanced cell therapies for cancer

Biotechnology
Healthcare

Compensation Overview

$255k - $280kAnnually

+ Annual Bonus + Equity Incentive Plan

Senior, Expert

Seattle, WA, USA + 1 more

More locations: Washington, USA

Role can be based in Seattle, WA or South San Francisco, CA.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Communications
Requirements
  • PhD or PharmD with a minimum of 15 years’ scientific and/or clinical experience in immunology, oncology, molecular biology, health care delivery, or
  • MSc with a minimum of 17 years’ scientific and/or clinical experience in immunology, oncology, molecular biology, health care delivery, or
  • BSRN with a minimum of 20 years’ scientific and/or clinical experience in immunology, oncology, molecular biology, health care delivery
  • A minimum of 5 years’ experience in clinical development, with substantial experience in the pharmaceutical industry contributing to successful clinical programs.
  • Phase 1 clinical trials experience.
  • Demonstrated experience in the design, execution, and oversight of clinical trials.
  • Strong analytical, organizational, and communication skills.
  • Ability to lead program/project teams effectively in a collaborative, fast-paced environment.
  • Ability to manage multiple priorities in a fast-paced, dynamic environment.
Responsibilities
  • Under guidance from the physician, drive the design and development of clinical trial protocols, ensuring they meet scientific, medical and regulatory requirements.
  • Prepare and review documents for regulatory submissions (IND, BLA, etc.), including clinical study reports, Investigator’s Brochures, and responses to regulatory agency inquiries.
  • Support the execution of clinical trials, ensuring adherence to the protocol, regulatory requirements, and Good Clinical Practice (GCP) guidelines.
  • Coordinate with data management teams to ensure accurate data collection, analysis, and reporting. Review and interpret clinical data to make informed decisions about study progression.
  • Monitor patient safety, identifying and managing adverse events, and ensuring timely reporting to regulatory bodies.
  • Provide leadership and support to clinical operations, biostatistics, regulatory affairs, and other departments to ensure seamless trial execution; identify issues and recommend solutions for immediate action.
  • Liaise with external stakeholders, including clinical research organizations (CROs), academic institutions, and key opinion leaders (KOLs); provide leadership and direction in identifying and solving issues to facilitate trial operations and maintain high standards of scientific integrity.
  • Define opportunities for innovation and improvement in clinical trial methodologies and therapeutic approaches.
  • Anticipate risk and proactively manage concerns; define actions to address issues in a timely manner.

Lyell Immunopharma develops advanced cell therapies aimed at treating solid tumors, which are cancerous tissue masses. The company focuses on enhancing T cells, a type of immune cell, to effectively target and eliminate cancer cells. Their approach includes genetic and epigenetic reprogramming of T cells to address challenges like T cell exhaustion and to ensure T cells can persist in the body. Unlike many competitors, Lyell is dedicated to creating curative treatments specifically for solid tumors, utilizing a diverse product pipeline that explores various treatment methods. The goal is to push the limits of current cancer therapies and provide effective solutions where traditional treatments have not succeeded.

Company Stage

IPO

Total Funding

$479.6M

Headquarters

San Francisco, California

Founded

2018

Growth & Insights
Headcount

6 month growth

0%

1 year growth

-17%

2 year growth

-13%
Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of ImmPACT Bio enhances Lyell's T-cell therapy capabilities.
  • Experienced leadership team strengthens strategic direction and operational efficiency.
  • New manufacturing facility in Bothell boosts production capacity and technology scaling.

What critics are saying

  • Increased competition in CAR T-cell therapies may impact market share.
  • Delays in clinical data results could affect investor confidence.
  • Regulatory scrutiny on reprogramming technologies may delay product approvals.

What makes Lyell Immunopharma unique

  • Lyell focuses on T cell reprogramming to treat solid tumors effectively.
  • Their Gen-R and Epi-R platforms address T cell exhaustion and stemness loss.
  • Lyell's dual-targeting CAR T-cell therapies offer innovative cancer treatment solutions.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE